169 related articles for article (PubMed ID: 20090516)
1. MUC16 expression and risk of adenocarcinoma metastases to peritoneum, pleura, leptomeninges, and brain.
Johnson MD; Vito F; Xu H
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):250-3. PubMed ID: 20090516
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
3. Do mesothelin/MUC16 interactions facilitate adenocarcinoma metastases to intracranial meningiomas?
Johnson MD
Surg Neurol Int; 2016; 7(Suppl 41):S1049-S1052. PubMed ID: 28144481
[TBL] [Abstract][Full Text] [Related]
4. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
[TBL] [Abstract][Full Text] [Related]
5. Mesothelin expression in the leptomeninges and meningiomas.
Johnson MD; Vito F; O'Connell MJ
J Histochem Cytochem; 2008 Jun; 56(6):579-85. PubMed ID: 18347077
[TBL] [Abstract][Full Text] [Related]
6. The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies.
Galloway ML; Murray D; Moffat DF
Histopathology; 2006 May; 48(6):767-9. PubMed ID: 16681698
[No Abstract] [Full Text] [Related]
7. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.
Coelho R; Marcos-Silva L; Ricardo S; Ponte F; Costa A; Lopes JM; David L
Expert Rev Anticancer Ther; 2018 Feb; 18(2):177-186. PubMed ID: 29241375
[TBL] [Abstract][Full Text] [Related]
9. Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium.
Bruney L; Conley KC; Moss NM; Liu Y; Stack MS
Biol Chem; 2014 Oct; 395(10):1221-31. PubMed ID: 25205731
[TBL] [Abstract][Full Text] [Related]
10. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.
Rump A; Morikawa Y; Tanaka M; Minami S; Umesaki N; Takeuchi M; Miyajima A
J Biol Chem; 2004 Mar; 279(10):9190-8. PubMed ID: 14676194
[TBL] [Abstract][Full Text] [Related]
11. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.
Hassan R; Laszik ZG; Lerner M; Raffeld M; Postier R; Brackett D
Am J Clin Pathol; 2005 Dec; 124(6):838-45. PubMed ID: 16416732
[TBL] [Abstract][Full Text] [Related]
12. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma.
Shimizu A; Hirono S; Tani M; Kawai M; Okada K; Miyazawa M; Kitahata Y; Nakamura Y; Noda T; Yokoyama S; Yamaue H
Cancer Sci; 2012 Apr; 103(4):739-46. PubMed ID: 22320398
[TBL] [Abstract][Full Text] [Related]
13. Mesothelin expression in human lung cancer.
Ho M; Bera TK; Willingham MC; Onda M; Hassan R; FitzGerald D; Pastan I
Clin Cancer Res; 2007 Mar; 13(5):1571-5. PubMed ID: 17332303
[TBL] [Abstract][Full Text] [Related]
14. A binding domain on mesothelin for CA125/MUC16.
Kaneko O; Gong L; Zhang J; Hansen JK; Hassan R; Lee B; Ho M
J Biol Chem; 2009 Feb; 284(6):3739-49. PubMed ID: 19075018
[TBL] [Abstract][Full Text] [Related]
15. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.
Garg G; Gibbs J; Belt B; Powell MA; Mutch DG; Goedegebuure P; Collins L; Piwnica-Worms D; Hawkins WG; Spitzer D
BMC Cancer; 2014 Jan; 14():35. PubMed ID: 24447304
[TBL] [Abstract][Full Text] [Related]
16. Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter.
Tan K; Kajino K; Momose S; Masaoka A; Sasahara K; Shiomi K; Izumi H; Abe M; Ohtsuji N; Wang T; Hino O; Fujii H
Hum Pathol; 2010 Sep; 41(9):1330-8. PubMed ID: 20573372
[TBL] [Abstract][Full Text] [Related]
17. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.
Creaney J; Yeoman D; Naumoff LK; Hof M; Segal A; Musk AW; De Klerk N; Horick N; Skates SJ; Robinson BW
Thorax; 2007 Jul; 62(7):569-76. PubMed ID: 17356060
[TBL] [Abstract][Full Text] [Related]
18. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.
Scholler N; Garvik B; Hayden-Ledbetter M; Kline T; Urban N
Cancer Lett; 2007 Mar; 247(1):130-6. PubMed ID: 16677756
[TBL] [Abstract][Full Text] [Related]
19. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.
Chen SH; Hung WC; Wang P; Paul C; Konstantopoulos K
Sci Rep; 2013; 3():1870. PubMed ID: 23694968
[TBL] [Abstract][Full Text] [Related]
20. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]